Kevin J. Scanlon, Ph.D.
Founder and CEO

[Arrow] We are at the threshold of a medical revolution for the diagnosis and treatment of human disease. Our Mission at International BioScience is to integrate the Creative Knowledge of Science with the Core Disciplines of Business Development Strategies

[Arrow] Dr. Kevin J. Scanlon's career has included: academic medicine, senior management in the pharmaceutical industry, CEO of four start-up companies and chairman of an angel investment group. Some examples of his experiences includes the following:

  • Currently, Dr. Scanlon is Professor of Practice at the D'Amore-McKim School of Business, Northeastern University. His course focuses on helping ventures achieve external funding. The course, New Tech Venture Growth Strategies, teaches the framework for developing a growth-focused product or service strategy, how to evolve a startup team, creating scalable business models & early stage venture finance. Working in student teams, they will develop business plans, create financial projections and investor packages for early stage ventures. Deliverables will include a due diligence package, a term sheet, and a presentation for investors. This course is a practicum on what it takes to get new venture concepts funded and scaled from the perspective of the entrepreneur, the customer and the investor.— (Teaching)
  • Dr. Kevin Scanlon has been in the investment community for 12 years. Currently, he is an investment advisor for Sky Ventures in Boston, MA. He was Chairman of Pasadena Angels Investment Group. This organization has supported entrepreneurs with seed round investments that have novel technology. Read his Entrepreneurial Economy [in Adobe PDF Format] article from the Technolink Association Newsletter. (Investment Community)
  • A video on Non-Government Funding by the Pharmaceutical Industry and Investors for Medical Research by Dr. Scanlon for Harvard University.
  • Dr. Kevin Scanlon has been CEO of four biotechnology companies. Melanoma Diagnostics has an six gene assay that can discriminated moles from melanoma. This company was sold to Myriad Genetics, Inc. (Salt Lake City, UT).
  • As a Pharmaceutical Industry-Vice President at Berlex-Schering AG (Berlin, Germany), he was responsible for the company's international cancer program in the US, Europe and Asia. (Industry)
  • Dr. Scanlon received his Ph.D. degree from the University of London in Molecular Biology and trained in Cancer Research at Yale Medical School. He was a Leukemia Society Scholar, awarded the Paul Martini Medical Research Prize in Cancer (Germany), was the past President of the International Society of Cell and Cancer Gene Therapy (England), was a participant at 400th Anniversary of Uppsala University (Sweden), is an advisor for the National Institute for Cellular Biotechnology (Ireland), Co-Founder of the Nature Journal, "Cancer Gene Therapy", co-authored over 137 original scientific articles, edited nine medical books and has seven issued patents. (Science)
BiographyEventsArticlesAngel InvestingBoardsConsultingIndustry
TeachingScienceBiotech CenterPhotosWebcastsLinksContact Us

You are visitor number 355,276 to the KJScanlon website.

Baywalk MarketingTop of Page